Attached files
| file | filename |
|---|---|
| EX-99.1 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v196555_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date
of Report (Date of Earliest Event Reported):
|
September
14, 2010
|
WEIKANG
BIO-TECHNOLOGY
GROUP CO., INC.
__________________________________________
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52350
|
26-2816569
|
|
____________________
(State
or other jurisdiction
|
__________
(Commission
|
____________
(I.R.S.
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
No. 365
Chengde Street, Daowai District, Harbin
Heilongjiang
Province, PRC 150020
_________________________________
(Address
of principal executive offices, including zip code)
|
Registrant’s
telephone number, including area code:
|
(86)
451 8835 5530
|
Not
Applicable
______________________________________________
Former
name or former address, if changed since last report
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure.
On
September 14, 2010, Weikang Bio-Technology Group Co., Inc. ("we", "us" or "the
Company") issued a press release in which we announced 2010 and 2011 fiscal year
guidance. A copy of the press release is furnished as Exhibit 99.1 to this
report. Exhibit 99.1 shall not be treated as filed for purposes of the
Securities Exchange Act of 1934, as amended.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
99.1
Press release issued by Weikang Bio-Technology Group Co., Inc. on September 14,
2010
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Weikang
Bio-Technology Group Co., Inc.
|
|||
|
|
|||
|
September
14, 2010
|
By:
|
/s/Yin
Wang
|
|
|
Name:
Yin Wang
|
|||
|
Title:
Chief Executive Officer
|
|||
Exhibit Index
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
release issued by Weikang Bio-Technology Group Co., Inc. on September 14,
2010
|